← Eichor
Study identifier: NCT06024824 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Dose-Painted Intensity Modulated Radiotherapy Pancreas (DP-IMRT Pancreas)

Condition: Pancreatic Adenocarcinoma  ·  Sponsor: Cancer Trials Ireland

PhasePhase 1/Phase 2
Planned participants49
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a prospective non-randomised Phase I/II Radiotherapy (RT) study with patients recruited to escalated dose cohorts. Patients with resectable or borderline resectable (per the National Comprehensive Cancer Network (NCCN) criteria) pancreatic adenocarcinoma will receive dose-escalated hypofractionated DP-IMRT via Intensity Modulated Radiotherapy (IMRT) / Volume Modulated Arc Therapy (VMAT).

This description comes directly from the study's public registry record.

Talk to the study team

Cancer Trials Ireland  ·  +35316677211  ·  info@cancertrials.ie

Always discuss trial participation with your own doctor first.

Locations (2)

St Luke's Radiation Oncology Network (SLRON)Dublin, IrelandRecruiting
St Vincent's University HospitalDublin, IrelandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06024824